What pricing range and discount to recent market price are the selling affiliates targeting, and what are the expected underwriting fees?

Pricing and discount – The secondary‑offering press‑release only states that the 20 million shares are being sold by affiliates of Warburg Pincus and GTCR. It does not disclose the actual price range that the affiliates are targeting, nor the percentage discount they are seeking relative to Sotera Health’s most recent quoted market price. In other words, the filing does not give a concrete “$X‑$Y per share” range or a “‑Z % discount” figure.

Under‑writing fees – Similarly, the announcement does not specify the under‑writing spread or any other placement‑agent compensation. The filing notes that the company will cover the offering expenses under its Registration Rights Agreement, but the exact dollar or percentage amount of the underwriting fees is omitted.

Trading implications – Because the pricing parameters and fee structure are absent, market participants will have to wait for the accompanying prospectus or the official pricing notice (typically released a few days before the sale) to gauge the depth of the discount and the cost of the transaction. Until those details are known, the secondary‑offering is likely to keep the share‑price volatility modest; investors can focus on the fundamentals of Sotera Health (its recent earnings, cash‑flow profile, and the strategic rationale for the affiliate recap) and the technical trend (the stock has been trading in a tight range around its recent lows, suggesting limited upside unless the offering is priced at a meaningful discount). In the meantime, a cautious short‑to‑neutral stance may be warranted, with a watch‑list for the upcoming pricing announcement.